<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01114529</url>
  </required_header>
  <id_info>
    <org_study_id>CRAD001A2429</org_study_id>
    <secondary_id>2009-015918-22</secondary_id>
    <nct_id>NCT01114529</nct_id>
  </id_info>
  <brief_title>Efficacy, Safety and Evolution of Cardiovascular Parameters in Renal Transplant Recipients</brief_title>
  <acronym>ELEVATE</acronym>
  <official_title>A 24-month, Multi-center, Open-label, Randomized, Controlled Trial to Investigate Efficacy, Safety and Evolution of Cardiovascular Parameters in de Novo Renal Transplant Recipients After Early Calcineurin Inhibitor to Everolimus Conversion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to determine whether an early Calcineurin Inhibitor (CNI) to
      everolimus conversion at 10-14 weeks post transplantation improves renal allograft function
      without compromising efficacy compared to standard CNI treatment in de novo renal allograft
      recipients. In addition, the study was designed to evaluate the impact of a CNI-free regimen
      on evolution of cardiovascular parameters in de novo renal allograft recipients
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a 24-month, multi-center, randomized, open-label trial with two parallel arms in
      adult de novo renal allograft recipients. The study consisted of a run-in period from
      transplantation to Randomization and a treatment period from Randomization until Month 24. At
      baseline visit, patients were transplanted and entered the run-in period from transplantation
      (Baseline) to Randomization (week 10-14 post-transplantation). At Week 10-14, eligible
      patients were randomized into one of the 2 treatment arms: standard CNIs and Myfortic versus
      everolimus and Myfortic and entered the treatment period of the study from Randomization to
      Month 24. Patients in both arms received steroids as per center practice and in any caseat
      least 5 mg/Day. At Randomization, patients were stratified according to their renal allograft
      function and previous cardiovascular events. The main analysis was performed at Month 12 and
      the follow-up analysis was performed at Month 24.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 9, 2010</start_date>
  <completion_date type="Actual">October 30, 2014</completion_date>
  <primary_completion_date type="Actual">October 30, 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Estimated Glomerular Filtration Rate (eGFR)</measure>
    <time_frame>Month 12</time_frame>
    <description>Assessment of renal function by comparing change from randomization to Month 12 in eGFR (MDRD4) between treatment arms (Full analysis set). Renal function was assessed by estimated Glomerular Filtration Rate (eGFR) using the Modification of Diet in Renal Disease (MDRD) formula. MDRD formula: GFR [mL/min/1.73m˄2] = 186.3*(C˄-1.154)*(A˄-0.203)*G*R. DEFINITIONS: C = serum concentration of creatinine [mg/dL]; A = age [years]; G = 0.742 when gender is female, otherwise G = 1; R = 1.21 when race is black, otherwise R = 1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Composite Efficacy Endpoint for Each Arm at Month 12 and Month 24</measure>
    <time_frame>at 12 months and month 24 post-transplantation</time_frame>
    <description>Efficacy failure rate used the composite endpoint of: (1) treated biopsy-proven acute rejection (BPAR)*, (2) graft loss**, or (3) death . *A treated BPAR was defined as a biopsy graded IA, IB, IIA, IIB, or III and which was treated with anti-rejection therapy. **Graft loss is defined as when the allograft was presumed lost on the day the participant started dialysis and was not able to subsequently be removed from dialysis or re-transplanted.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Left Ventricular Mass Index (LVMi) From Randomization to Month 12 and Month 24</measure>
    <time_frame>Randomization, Month 12 and Month 24</time_frame>
    <description>Evolution of left ventricular mass and hypertrophy were evaluated by left ventricular mass index (LVMi) assessed by echocardiography. LVMi is derived using a standard formula from dimensional measurements on the echocardiogram. Analysis of covariance was applied with treatment, center (as a random effect), and donor type as factors and LVMi at Randomization as covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of Incidence Rates of Efficacy Endpoints Between Treatment Arms (Full Analysis Set - 24 Month Analysis)</measure>
    <time_frame>at 24 months post-transplantation</time_frame>
    <description>(treated BPAR ≥ IB, graft loss or death)A comparison of the incidence rates for the individual components of the composite efficacy endpoint between treatment arms</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">828</enrollment>
  <condition>Kidney Transplantation</condition>
  <arm_group>
    <arm_group_label>Everolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Conversion from CNI to everolimus in combination with Myfortic and steroids</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Calcineurin inhibitor, Prograf or Neoral</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Control arm: CNI continuation, either Prograf or Neoral in combination with Myfortic and steroids</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus</intervention_name>
    <description>Early CNI to everolimus conversion</description>
    <arm_group_label>Everolimus</arm_group_label>
    <other_name>Certican, Zortress, RAD001</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prograf or Neoral</intervention_name>
    <description>Active CNI-based control (Prograf or Neoral)</description>
    <arm_group_label>Calcineurin inhibitor, Prograf or Neoral</arm_group_label>
    <other_name>Tacrolimus or Cyclosporine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria at Baseline:

          -  Male or female renal allograft recipients at least 18 years old.

          -  Written informed consent.

          -  Patient receiving a primary or secondary kidney transplant from a cadaveric or living
             unrelated-/related donor.

          -  Cold ischemia time (CIT) &lt; 24 hours.

          -  Negative pregnancy test for female patients.

        Inclusion Criteria at Randomization:

          -  Patients on CNI (TAC or CsA) + Myfortic + steroids.

          -  Serum creatinine &lt; 2.8 mg/dL (250 µmol/L) and an actual eGFR (MDRD4) ≥ 25 mL/min/1.73m
             exp2 (without renal replacement therapy).

        Exclusion Criteria at Baseline:

        Patients fulfilling any of the following criteria are not eligible for inclusion in this
        study:

          -  Recipient of multiple organ transplants.

          -  Recipient of ABO incompatible allograft or a positive cross-match.

          -  Panel Reactive Antibodies (PRA) level ≥ 30 %.

          -  Positive test for human immunodeficiency virus (HIV).

          -  Patient receiving an allograft from a Hepatitis B surface Antigen (HBsAg) or a
             Hepatitis C Virus (HCV) positive donor.

          -  HBsAg and/or a HCV positive patient with evidence of elevated LFTs (ALT/AST levels ≥
             2.5 times ULN).

          -  Severe restrictive or obstructive pulmonary disorders.

          -  Patient with severe allergy requiring acute or chronic treatment or hypersensitivity
             to any of the study drugs or similar drugs.

          -  Severe hypercholesterolemia or hypertriglyceridemia.

          -  Low platelet count.

          -  Low white blood cell count.

          -  History of malignancy of any organ system

        Exclusion Criteria at Randomization:

          -  Graft loss.

          -  Patient on renal replacement therapy.

          -  Patient who experienced severe humoral and/or cellular rejection (BANFF ≥ IIb).

          -  Patient with ≥ 2 episodes of AR or an AR episode that needed antibody treatment.

          -  Patient with ongoing or currently treated AR (2 weeks prior to randomization).

          -  Proteinuria &gt; 1 g/day.

          -  Patients with recurrence of Focal Segmental Glomerulosclerosis (FSGS).

          -  Low platelet count; Low white blood cell count; Low absolute neutrophil count; Low
             hemoglobin.

          -  Severe liver disease.

          -  Systemic infection requiring continued therapy that would interfere with the
             objectives of the study.

          -  Severe hypercholesterolemia or hypertriglyceridemia.

          -  Patients with ongoing wound healing problems, clinically significant infection
             requiring continued therapy.

          -  Presence of intractable immunosuppressant complications or side effects.

          -  Patients on anticoagulants that prevents renal allograft biopsy.

          -  Use of prohibited medication.

          -  Use of immunosuppressive agents not utilized in the protocol.

          -  Pregnant or nursing (lactating) women.

          -  Women of child-bearing potential not using a highly effective method of birth control.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Caba</city>
        <state>Buenos Aires</state>
        <zip>C1118AAT</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Martin</city>
        <state>Buenos Aires</state>
        <zip>C1107BEA</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Resistencia</city>
        <state>Chaco</state>
        <zip>H3508AZP</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cordoba</city>
        <zip>X5016JDA</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cordoba</city>
        <zip>X5016KEH</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cordoba</city>
        <zip>X5022CPU</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Santa Fe</city>
        <zip>S3000EPV</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Linz</city>
        <zip>A-4010</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Linz</city>
        <zip>A-4020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tartu</city>
        <zip>51014</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Brest</city>
        <zip>29200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nice Cedex 1</city>
        <zip>06602</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toulouse Cedex 4</city>
        <zip>31054</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tours Cedex</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vandoeuvre Les Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>12203</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>60596</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hannover Muenden</city>
        <zip>34346</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Muenster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Athens</city>
        <zip>GR 11527</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Athens</city>
        <zip>GR-106 76</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Patras</city>
        <zip>265 00</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vishakhapatnam</city>
        <state>Andhra Pradesh</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <zip>110017</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560 055</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lucknow</city>
        <state>Uttar Pradesh</state>
        <zip>226014</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>New Delhi</city>
        <zip>110044</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bologna</city>
        <state>BO</state>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Padova</city>
        <state>PD</state>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00144</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Siena</city>
        <state>SI</state>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Torino</city>
        <state>TO</state>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Riga</city>
        <zip>1002</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vilnius</city>
        <zip>LT-08661</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Torreón</city>
        <state>Coahuila</state>
        <zip>27250</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mexico</city>
        <state>Distrito Federal</state>
        <zip>14080</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Aguascalientes</city>
        <zip>20230</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Veracruz</city>
        <zip>91700</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leiden</city>
        <zip>2300 RC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Oslo</city>
        <zip>0424</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Carnaxide - Linda-A-Velha</city>
        <state>Lisboa</state>
        <zip>2790-134</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lisbon</city>
        <zip>1069-166</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Porto</city>
        <zip>4200-319</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cluj-Napoca</city>
        <state>Jud Cluj</state>
        <zip>400006</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Krasnodar</city>
        <zip>350086</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>115446</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>123182</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nizhnii Novgorod</city>
        <zip>603000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630087</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>S.-Petersburg</city>
        <zip>192242</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Samara</city>
        <zip>443079</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Volzhskiy</city>
        <zip>404120</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Malaga</city>
        <state>Andalucia</state>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Santander</city>
        <state>Cantabria</state>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hospitalet de Llobregat</city>
        <state>Cataluña</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>A Coruña</city>
        <state>Galicia</state>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Khon Kaen</city>
        <state>THA</state>
        <zip>40002</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Antalya</city>
        <zip>07000</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Büyükçekmece / Ýstanbul</city>
        <zip>34520</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fatih / Istanbul</city>
        <zip>34098</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Istanbul</city>
        <zip>34093</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Estonia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>India</country>
    <country>Italy</country>
    <country>Latvia</country>
    <country>Lithuania</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Portugal</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Thailand</country>
    <country>Turkey</country>
  </location_countries>
  <removed_countries>
    <country>Taiwan</country>
  </removed_countries>
  <link>
    <url>https://doi.org/10.1111/ajt.13898</url>
    <description>The American Journal of Transplantation, Poster Abstracts, 2016
Provider: John Wiley &amp; Sons, Ltd</description>
  </link>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 27, 2010</study_first_submitted>
  <study_first_submitted_qc>April 29, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 3, 2010</study_first_posted>
  <results_first_submitted>October 26, 2015</results_first_submitted>
  <results_first_submitted_qc>April 24, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">May 30, 2017</results_first_posted>
  <last_update_submitted>April 24, 2017</last_update_submitted>
  <last_update_submitted_qc>April 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>de novo renal allograft recipients</keyword>
  <keyword>renal allograft function</keyword>
  <keyword>CNI-free regimen</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Calcineurin Inhibitors</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Full analysis set (24 month analysis)</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Everolimus</title>
          <description>Conversion from Calcineurin inhibitor (CNI) to everolimus in combination with Myfortic (mycophenolic acid) and steroids</description>
        </group>
        <group group_id="P2">
          <title>Standard CNI (Tac)</title>
          <description>Calcineurin inhibitor (CNI) continuation with Tacrolimus (Tac) in combination with Myfortic (mycophenolic acid), and steroids</description>
        </group>
        <group group_id="P3">
          <title>Standard CNI (CsA)</title>
          <description>Calcineurin inhibitor (CNI) continuation with Cyclosporine (CsA) in combination with Myfortic (mycophenolic acid) and steroids</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Completed Study Medication at Month 24</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="353">Randomized set - 360 Full analysis set - 353 Safety analysis set -346*</participants>
                <participants group_id="P2" count="231">Randomized set -231 Full analysis set -231 Safety analysis set -238**</participants>
                <participants group_id="P3" count="125">Randomized set-125 Full analysis set -125 Safety analysis set -121***</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="229">completed at month 24</participants>
                <participants group_id="P2" count="190">completed at month 24</participants>
                <participants group_id="P3" count="93">completed at month 24</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="124"/>
                <participants group_id="P2" count="41"/>
                <participants group_id="P3" count="32"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="87"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="17"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Abnormal laboratory value(s)</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Abnormal test procedure result(s)</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject's no longer required drug</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative problems</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Graft loss</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Missing</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Completed Study Phase at Month 24</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="353">It includes those discontinued treatment</participants>
                <participants group_id="P2" count="231">It includes those discontinued treatment</participants>
                <participants group_id="P3" count="125">It includes those discontinued treatment</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="313">at month 24</participants>
                <participants group_id="P2" count="215">at month 24</participants>
                <participants group_id="P3" count="111">at month 24</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="14"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Missing</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Full analysis set (FAS), 24 month analysis</population>
      <group_list>
        <group group_id="B1">
          <title>Everolimus</title>
          <description>Conversion from Calcineurin inhibitor (CNI) to everolimus in combination with Myfortic (mycophenolic acid) and steroids</description>
        </group>
        <group group_id="B2">
          <title>Standard CNI (Tac)</title>
          <description>Calcineurin inhibitor (CNI) continuation with Tacrolimus (Tac) in combination with Myfortic (mycophenolic acid), and steroids</description>
        </group>
        <group group_id="B3">
          <title>Standard CNI (CsA)</title>
          <description>Calcineurin inhibitor (CNI) continuation with Cyclosporine (CsA) in combination with Myfortic (mycophenolic acid) and steroids</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="353"/>
            <count group_id="B2" value="231"/>
            <count group_id="B3" value="125"/>
            <count group_id="B4" value="709"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Kidney transplant Recipients age in years</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.0" spread="14.4"/>
                    <measurement group_id="B2" value="47.3" spread="14.5"/>
                    <measurement group_id="B3" value="45.4" spread="15.6"/>
                    <measurement group_id="B4" value="46.2" spread="14.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="111"/>
                    <measurement group_id="B2" value="71"/>
                    <measurement group_id="B3" value="33"/>
                    <measurement group_id="B4" value="215"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="242"/>
                    <measurement group_id="B2" value="160"/>
                    <measurement group_id="B3" value="92"/>
                    <measurement group_id="B4" value="494"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="246" spread="69.7"/>
                    <measurement group_id="B2" value="173" spread="74.9"/>
                    <measurement group_id="B3" value="97" spread="77.6"/>
                    <measurement group_id="B4" value="516"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4" spread="1.1"/>
                    <measurement group_id="B2" value="5" spread="2.2"/>
                    <measurement group_id="B3" value="0" spread="0"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66" spread="18.7"/>
                    <measurement group_id="B2" value="41" spread="17.7"/>
                    <measurement group_id="B3" value="20" spread="16.0"/>
                    <measurement group_id="B4" value="127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1" spread="0.3"/>
                    <measurement group_id="B2" value="0" spread="0.0"/>
                    <measurement group_id="B3" value="0" spread="0.0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0" spread="0"/>
                    <measurement group_id="B2" value="1" spread="0.4"/>
                    <measurement group_id="B3" value="1" spread="0.8"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36" spread="10.2"/>
                    <measurement group_id="B2" value="11" spread="4.8"/>
                    <measurement group_id="B3" value="7" spread="5.6"/>
                    <measurement group_id="B4" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Estimated Glomerular Filtration Rate (eGFR)</title>
        <description>Assessment of renal function by comparing change from randomization to Month 12 in eGFR ‎‎(MDRD4) between treatment arms (Full analysis set). Renal function was assessed by estimated Glomerular Filtration Rate (eGFR) using the Modification of Diet in Renal Disease (MDRD) formula. MDRD formula: GFR [mL/min/1.73m˄2] = 186.3*(C˄-1.154)*(A˄-0.203)*G*R. DEFINITIONS: C = serum concentration of creatinine [mg/dL]; A = age [years]; G = 0.742 when gender is female, otherwise G = 1; R = 1.21 when race is black, otherwise R = 1‎</description>
        <time_frame>Month 12</time_frame>
        <population>Full Analysis set - observed eGFR values at month 12 (counted the patients with available values)</population>
        <group_list>
          <group group_id="O1">
            <title>Everolimus</title>
            <description>Conversion from Calcineurin inhibitor (CNI) to everolimus in combination with Myfortic (mycophenolic acid) and steroids</description>
          </group>
          <group group_id="O2">
            <title>Standard CNI (Tac)</title>
            <description>Calcineurin inhibitor (CNI) continuation with Tacrolimus (Tac) in combination with Myfortic (mycophenolic acid) and steroids</description>
          </group>
          <group group_id="O3">
            <title>Standard CNI (CsA)</title>
            <description>Calcineurin inhibitor (CNI) continuation with Cyclosporine (CsA) in combination with Myfortic (mycophenolic acid), and steroids</description>
          </group>
        </group_list>
        <measure>
          <title>Estimated Glomerular Filtration Rate (eGFR)</title>
          <description>Assessment of renal function by comparing change from randomization to Month 12 in eGFR ‎‎(MDRD4) between treatment arms (Full analysis set). Renal function was assessed by estimated Glomerular Filtration Rate (eGFR) using the Modification of Diet in Renal Disease (MDRD) formula. MDRD formula: GFR [mL/min/1.73m˄2] = 186.3*(C˄-1.154)*(A˄-0.203)*G*R. DEFINITIONS: C = serum concentration of creatinine [mg/dL]; A = age [years]; G = 0.742 when gender is female, otherwise G = 1; R = 1.21 when race is black, otherwise R = 1‎</description>
          <population>Full Analysis set - observed eGFR values at month 12 (counted the patients with available values)</population>
          <units>mL/min/1.73m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="327"/>
                <count group_id="O2" value="213"/>
                <count group_id="O3" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.1" spread="22.31"/>
                    <measurement group_id="O2" value="61.5" spread="19.86"/>
                    <measurement group_id="O3" value="58.4" spread="19.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Composite Efficacy Endpoint for Each Arm at Month 12 and Month 24</title>
        <description>Efficacy failure rate used the composite endpoint of: (1) treated biopsy-proven acute rejection (BPAR)*, (2) graft loss**, or (3) death . *A treated BPAR was defined as a biopsy graded IA, IB, IIA, IIB, or III and which was treated with anti-rejection therapy. **Graft loss is defined as when the allograft was presumed lost on the day the participant started dialysis and was not able to subsequently be removed from dialysis or re-transplanted.</description>
        <time_frame>at 12 months and month 24 post-transplantation</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Everolimus</title>
            <description>Conversion from Calcineurin inhibitor (CNI) to everolimus in combination with Myfortic (mycophenolic acid) and steroids</description>
          </group>
          <group group_id="O2">
            <title>Standard CNI (Tac)</title>
            <description>Calcineurin inhibitor (CNI) continuation with Tacrolimus (Tac) in combination with Myfortic (mycophenolic acid), and steroids</description>
          </group>
          <group group_id="O3">
            <title>Standard CNI (CsA)</title>
            <description>Calcineurin inhibitor (CNI) continuation with Cyclosporine (CsA) in combination with Myfortic (mycophenolic acid) and steroids</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Composite Efficacy Endpoint for Each Arm at Month 12 and Month 24</title>
          <description>Efficacy failure rate used the composite endpoint of: (1) treated biopsy-proven acute rejection (BPAR)*, (2) graft loss**, or (3) death . *A treated BPAR was defined as a biopsy graded IA, IB, IIA, IIB, or III and which was treated with anti-rejection therapy. **Graft loss is defined as when the allograft was presumed lost on the day the participant started dialysis and was not able to subsequently be removed from dialysis or re-transplanted.</description>
          <population>Full Analysis Set</population>
          <units>Number of incidence</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="359"/>
                <count group_id="O2" value="231"/>
                <count group_id="O3" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Left Ventricular Mass Index (LVMi) From Randomization to Month 12 and Month 24</title>
        <description>Evolution of left ventricular mass and hypertrophy were evaluated by left ventricular mass index (LVMi) assessed by echocardiography. LVMi is derived using a standard formula from dimensional measurements on the echocardiogram. Analysis of covariance was applied with treatment, center (as a random effect), and donor type as factors and LVMi at Randomization as covariate.</description>
        <time_frame>Randomization, Month 12 and Month 24</time_frame>
        <population>Full Analysis Set consists of only patients with triple LVMi values available at randomization, Month 12 and month 24 are included</population>
        <group_list>
          <group group_id="O1">
            <title>Everolimus</title>
            <description>Conversion from Calcineurin inhibitor (CNI) to everolimus in combination with Myfortic (mycophenolic acid) and steroids</description>
          </group>
          <group group_id="O2">
            <title>Standard CNI (Tac)</title>
            <description>Calcineurin inhibitor (CNI) continuation with Tacrolimus (Tac) in combination with Myfortic (mycophenolic acid) and steroids</description>
          </group>
          <group group_id="O3">
            <title>Standard CNI (CsA)</title>
            <description>Calcineurin inhibitor (CNI) continuation with Cyclosporine (CsA) in combination with Myfortic (mycophenolic acid), and steroids</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Left Ventricular Mass Index (LVMi) From Randomization to Month 12 and Month 24</title>
          <description>Evolution of left ventricular mass and hypertrophy were evaluated by left ventricular mass index (LVMi) assessed by echocardiography. LVMi is derived using a standard formula from dimensional measurements on the echocardiogram. Analysis of covariance was applied with treatment, center (as a random effect), and donor type as factors and LVMi at Randomization as covariate.</description>
          <population>Full Analysis Set consists of only patients with triple LVMi values available at randomization, Month 12 and month 24 are included</population>
          <units>g/m^2.7</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="180"/>
                <count group_id="O2" value="156"/>
                <count group_id="O3" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Randomization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.30" spread="11.62"/>
                    <measurement group_id="O2" value="51.08" spread="14.11"/>
                    <measurement group_id="O3" value="51.13" spread="12.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.95" spread="12.63"/>
                    <measurement group_id="O2" value="48.98" spread="14.63"/>
                    <measurement group_id="O3" value="50.96" spread="13.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.66" spread="12.19"/>
                    <measurement group_id="O2" value="45.63" spread="13.50"/>
                    <measurement group_id="O3" value="47.91" spread="12.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparison of Incidence Rates of Efficacy Endpoints Between Treatment Arms (Full Analysis Set - 24 Month Analysis)</title>
        <description>(treated BPAR ≥ IB, graft loss or death)A comparison of the incidence rates for the individual components of the composite efficacy endpoint between treatment arms</description>
        <time_frame>at 24 months post-transplantation</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Everolimus</title>
            <description>Conversion from Calcineurin inhibitor (CNI) to everolimus in combination with Myfortic (mycophenolic acid) and steroids</description>
          </group>
          <group group_id="O2">
            <title>Standard CNI (Tac)</title>
            <description>Calcineurin inhibitor (CNI) continuation with Tacrolimus (Tac) in combination with Myfortic (mycophenolic acid), and steroids</description>
          </group>
          <group group_id="O3">
            <title>Standard CNI (CsA)</title>
            <description>Calcineurin inhibitor (CNI) continuation with Cyclosporine (CsA) in combination with Myfortic (mycophenolic acid) and steroids</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of Incidence Rates of Efficacy Endpoints Between Treatment Arms (Full Analysis Set - 24 Month Analysis)</title>
          <description>(treated BPAR ≥ IB, graft loss or death)A comparison of the incidence rates for the individual components of the composite efficacy endpoint between treatment arms</description>
          <population>Full Analysis Set</population>
          <units>Number of incidence</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="353"/>
                <count group_id="O2" value="231"/>
                <count group_id="O3" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Composite failure:‎ tBPAR&gt;=IB, graft loss, death‎</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Composite tBPAR&gt;=IB, graft loss, death, loss f/u</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Composite of graft loss or Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>tBPAR&gt;=IB</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Graft loss</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Suspected Acute rejection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subclinical Acute rejection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Acute rejection (AR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treated Acute rejection (tAR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>biopsy proven acute rejection (BPAR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>treated biopsy proven acute rejection (tBPAR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>tBPAR=IA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>tBPAR=IB</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>tBPAR=IIA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>tBPAR=IIB</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>tBPAR=III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Antibody tBPAR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Antibody mediated rejection (AMR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24 months</time_frame>
      <desc>Incidence of serious adverse events/infections by primary system organ class and preferred tem and treatment- Safety analysis set</desc>
      <group_list>
        <group group_id="E1">
          <title>Everolimus</title>
          <description>Conversion from Calcineurin inhibitor (CNI) to everolimus in combination with Myfortic (mycophenolic acid) and steroids</description>
        </group>
        <group group_id="E2">
          <title>Standard CNI (Tac)</title>
          <description>Calcineurin inhibitor (CNI) continuation with Tacrolimus (Tac) in combination with Myfortic (mycophenolic acid) and steroids</description>
        </group>
        <group group_id="E3">
          <title>Standard CNI (CsA)</title>
          <description>Calcineurin inhibitor (CNI) continuation with Cyclosporine (CsA) in combination with Myfortic (mycophenolic acid) and steroids</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>17.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="188" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="118" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="58" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Agranulocytosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Coagulopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Hypochromic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Lymphocytic infiltration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Normochromic normocytic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Thrombotic microangiopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Cyanosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Congenital cystic kidney disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperparathyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Anal fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Crohn's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Food poisoning</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Gastrointestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Gastrointestinal toxicity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Ileal fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Intestinal ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Mouth ulceration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Oedematous pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Subileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Device leakage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Generalised oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Impaired healing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Surgical failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Cholecystitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Hydrocholecystis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Liver disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Kidney transplant rejection</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Transplant rejection</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Arthritis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Asymptomatic bacteriuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>BK virus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Bacterial infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Bacterial pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Bacterial sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Catheter site abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Clostridium difficile infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Corona virus infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus viraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Dengue fever</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Diarrhoea infectious</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Escherichia urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Gastroenteritis norovirus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Gastrointestinal infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Gingivitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Graft infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>H1N1 influenza</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Herpes simplex</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Infected lymphocele</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Infectious pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Intervertebral discitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Kidney infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Liver abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Mastitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Metapneumovirus infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Ophthalmic herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Peritoneal tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Peritonsillar abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Pneumocystis jirovecii pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Pneumonia cytomegaloviral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Pneumonia klebsiella</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Pneumonia mycoplasmal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Polyomavirus-associated nephropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Post procedural infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Pulmonary sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Pyelonephritis chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Renal cyst infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Rhinovirus infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Salmonellosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Scrub typhus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Septic necrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Shunt infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Systemic candida</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Urinary tract infection bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Urinary tract infection fungal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Vestibular neuronitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Zygomycosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Abdominal wound dehiscence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Animal bite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Carbon monoxide poisoning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Cervical vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Colon injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Complications of transplanted kidney</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Face injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Graft dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Graft loss</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Incisional hernia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Limb traumatic amputation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Post procedural haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Postoperative wound complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Renal graft loss</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Shunt aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Shunt thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Toxicity to various agents</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Transplant dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Transplant failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Traumatic arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Ureteric anastomosis complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Vascular pseudoaneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Wound necrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Biopsy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Blood creatine increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Blood creatinine abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>C-reactive protein increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Creatinine renal clearance decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Haemoglobin urine present</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Protein urine present</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Diabetes with hyperosmolarity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Fluid retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Hyperosmolar state</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Obesity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Type 1 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Muscle haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Myopathy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Adenocarcinoma gastric</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Bowen's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Brain neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Bronchial carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Glioblastoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Hepatic cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Hepatic cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Invasive ductal breast carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Lentigo maligna</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Metastases to spine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Papillary thyroid cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Parathyroid tumour benign</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Rectal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Renal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Small cell lung cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Dementia Alzheimer's type</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Dementia with Lewy bodies</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Multifocal motor neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute prerenal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Bladder obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Calculus urinary</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Cystitis haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Kidney fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Nephritis haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Nephropathy toxic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Obstructive uropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Oliguria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Prerenal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Renal artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Renal cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Renal cyst haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Renal failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Renal tubular atrophy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Renal tubular necrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Tubulointerstitial nephritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Ureteric obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Ureteric stenosis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Urethral obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Urethral stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Urinary fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Urinary tract obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Epididymitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Pelvic haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Obstructive airways disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Pulmonary alveolar haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic foot</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arteriovenous fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Haemodynamic instability</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Lymphocele</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Lymphoedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Necrosis ischaemic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Peripheral artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Peripheral artery thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Vena cava thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Venous thrombosis limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>17.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="316" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="216" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="103" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="79" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Mouth ulceration</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="62" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Kidney transplant rejection</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Transplant rejection</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="75" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>BK virus infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus infection</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Dyslipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Hyperlipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Hematuria</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="121"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="346"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="238"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="121"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing any publications from a single-site are postponed until publication of the pooled data (i.e., data from all sites) in the clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>+1(862)778-8300</phone>
      <email>trialandresults.registries@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

